GlassScriptPhysician profile
Jeffrey A Maynard
NPI 1356889570
$2,502.05
in general payments reported to CMS, 2019-2025
16 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $68.72 · 2023: $606 · 2024: $432 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.06 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.91 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $436.80 | 2025 | Caplyta |
| Indivior INC. | $398.63 | 2023-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $231.74 | 2024-2025 | Rexulti |
| Braeburn INC. | $229.49 | 2023-2025 | Brixadi |
| Gilead Sciences, INC. | $146.62 | 2023 | Epclusa |
| Orexo US, INC. | $112.04 | 2022-2023 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $49.56 | 2024 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $46.14 | 2025 | Austedo Xr |
| Lundbeck LLC | $34.07 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $31.53 | 2024-2025 | Zenpep |
| Collegium Pharmaceutical, INC. | $21.39 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $14.80 | 2025 | Airsupra |
| Ironshore Pharmaceuticals INC. | $14.72 | 2024 | |
| Alkermes, INC. | $14.42 | 2025 | Vivitrol |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13.19 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.